BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32415564)

  • 21. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
    Endzinas Z; Mickevicius A; Kiudelis M
    Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
    Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
    Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
    Beilstein M; Silberg D
    Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
    Streppel MM; Pai S; Campbell NR; Hu C; Yabuuchi S; Canto MI; Wang JS; Montgomery EA; Maitra A
    Clin Cancer Res; 2013 Aug; 19(15):4067-78. PubMed ID: 23757351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
    Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
    Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
    Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
    Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma.
    Smith CM; Watson DI; Michael MZ; Hussey DJ
    World J Gastroenterol; 2010 Feb; 16(5):531-7. PubMed ID: 20128019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
    Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
    Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
    Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
    Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
    Maru DM; Singh RR; Hannah C; Albarracin CT; Li YX; Abraham R; Romans AM; Yao H; Luthra MG; Anandasabapathy S; Swisher SG; Hofstetter WL; Rashid A; Luthra R
    Am J Pathol; 2009 May; 174(5):1940-8. PubMed ID: 19342367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma.
    Hillman LC; Chiragakis L; Clarke AC; Kaushik SP; Kaye GL
    J Gastroenterol Hepatol; 2003 May; 18(5):526-33. PubMed ID: 12702044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosing Barrett's esophagus: reliability of clinical and pathologic diagnoses.
    Corley DA; Kubo A; DeBoer J; Rumore GJ
    Gastrointest Endosc; 2009 May; 69(6):1004-10. PubMed ID: 19152897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.